Tags

Type your tag names separated by a space and hit enter

[Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection].
Med Clin (Barc). 2020 08 28; 155(4):159-161.MC

Abstract

INTRODUCTION

Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19.

PATIENTS

We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable.

RESULTS

In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival.

DISCUSSION

The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.

Links

Publisher Full Text
ncbi.nlm.nih.gov
elsevier.es
linkinghub.elsevier.com
PMC Free PDF

Authors+Show Affiliations

Callejas Rubio JL
Unidad de Enfermedades Sistémicas, Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España. Electronic address: jlcalleja@telefonica.net.
Luna Del Castillo JD
Departamento de Bioestadística, Facultad de Medicina, Universidad de Granada, Granada, España.
de la Hera Fernández J
Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España.
Guirao Arrabal E
Unidad de Enfermedades Infecciosas, Hospital Universitario Clínico San Cecilio, Granada, España.
Colmenero Ruiz M
Servicio de Cuidados Intensivos, Hospital Universitario Clínico San Cecilio, Granada, España.
Ortego Centeno N
Unidad de Enfermedades Sistémicas, Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España.

MeSH

Adrenal Cortex HormonesAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBetacoronavirusCoronavirus InfectionsCytokine Release SyndromeDrug Administration ScheduleFemaleHumansIntubation, IntratrachealKaplan-Meier EstimateMaleMiddle AgedPandemicsPneumonia, ViralRetrospective Studies

Pub Type(s)

Case Reports
Observational Study

Language

eng spa

PubMed ID

32532461

Citation

Callejas Rubio, José Luis, et al. "[Effectiveness of Corticoid Pulses in Patients With Cytokine Storm Syndrome Induced By SARS-CoV-2 Infection]." Medicina Clinica, vol. 155, no. 4, 2020, pp. 159-161.
Callejas Rubio JL, Luna Del Castillo JD, de la Hera Fernández J, et al. [Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection]. Med Clin (Barc). 2020;155(4):159-161.
Callejas Rubio, J. L., Luna Del Castillo, J. D., de la Hera Fernández, J., Guirao Arrabal, E., Colmenero Ruiz, M., & Ortego Centeno, N. (2020). [Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection]. Medicina Clinica, 155(4), 159-161. https://doi.org/10.1016/j.medcli.2020.04.018
Callejas Rubio JL, et al. [Effectiveness of Corticoid Pulses in Patients With Cytokine Storm Syndrome Induced By SARS-CoV-2 Infection]. Med Clin (Barc). 2020 08 28;155(4):159-161. PubMed PMID: 32532461.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection]. AU - Callejas Rubio,José Luis, AU - Luna Del Castillo,Juan de Dios, AU - de la Hera Fernández,Javier, AU - Guirao Arrabal,Emilio, AU - Colmenero Ruiz,Manuel, AU - Ortego Centeno,Norberto, Y1 - 2020/05/27/ PY - 2020/04/10/received PY - 2020/04/18/revised PY - 2020/04/23/accepted PY - 2020/6/14/pubmed PY - 2020/8/28/medline PY - 2020/6/14/entrez KW - Coronavirus COVID-19 KW - Cytokine release synddrome KW - Hemofagocítico KW - Hemophagocytic KW - Síndrome de liberación de citocinas SP - 159 EP - 161 JF - Medicina clinica JO - Med Clin (Barc) VL - 155 IS - 4 N2 - INTRODUCTION: Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19. PATIENTS: We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable. RESULTS: In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival. DISCUSSION: The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death. SN - 1578-8989 UR - https://www.unboundmedicine.com/medline/citation/32532461/[Effectiveness_of_corticoid_pulses_in_patients_with_cytokine_storm_syndrome_induced_by_SARS_CoV_2_infection]_ L2 - http://www.elsevier.es/en/linksolver/ft/pii/S0025-7753(20)30283-9 DB - PRIME DP - Unbound Medicine ER -